DexCom, Inc. (DXCM) News
Follow DexCom, Inc. (DXCM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 49 public stories across 24 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
RBC Says DexCom Q3 Results and Higher Revenue Guidance Point to Stronger 2027
MT Newswires reports that DexCom posted better-than-expected Q3 results and higher revenue guidance; RBC says the results point to a stronger 2027.
EQUITY | Oct 30, 2026, 03:53 PM UTC
M
DexCom Reports Q3 Revenue of $1.34 Billion, Raises 2026 Guidance
DexCom reported Q3 2026 adjusted EPS of $0.73 and raised full-year revenue guidance to $5.20 billion–$5.25 billion. Revenue was $1.34 billion, versus FactSet consensus of $1.33 billion; adjusted EPS compared with an anal
EQUITY | Oct 29, 2026, 10:03 PM UTC
M
Dexcom Reports Third-Quarter Revenue of $1.34 Billion
Dexcom reported third-quarter 2026 revenue of $1.34 billion, up 11.2% year over year. Net income fell 3.1% to $275.1 million, while diluted EPS rose 2.9% to $0.72.
EQUITY | Oct 29, 2026, 09:31 PM UTC
M
DexCom Raises 2026 Revenue View to $5.20B–$5.25B
EARNINGS | Oct 29, 2026, 08:29 PM UTC
M
Dexcom authorizes share repurchase program of up to $1 billion
Dexcom authorized a share repurchase program of up to $1 billion, according to an SEC filing.
EQUITY | Oct 29, 2026, 08:24 PM UTC
M
Dexcom Beats Q3 EPS by $0.06, Guides FY26 Revenue In Line
Dexcom reported Q3 earnings of $0.73 per share, excluding non-recurring items, $0.06 above the comparison figure. It guided FY26 revenue in line.
EQUITY | Oct 29, 2026, 08:20 PM UTC
M
Dexcom Reports Q3 Adjusted EPS of $0.73 vs. $0.67 Estimate
EARNINGS | Oct 29, 2026, 08:08 PM UTC
M
Dexcom Reports Third-Quarter 2026 Financial Results
DexCom reported its third-quarter 2026 financial results.
EQUITY | Oct 29, 2026, 08:07 PM UTC
M
DexCom Q3'26 Earnings Preview
DexCom is scheduled to report Q3'26 results on October 29 after the market closes.
EQUITY | Oct 22, 2026, 11:01 AM UTC
L
Dexcom CONNECT Study published in New England Journal of Medicine
The study concerns people with type 2 diabetes who are not on insulin.
EQUITY | Oct 14, 2026, 09:15 PM UTC
M
US session market picture: S&P 500 +0.07%, Nasdaq 100 -0.18%; EUR/USD -0.22%, WTI +1.75%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.07 percent, Nasdaq futures is down 0.18 percent, Dow futures is up 0.02 percent and Russell futures is down 0.1 percent. In currencies, the dollar inde
EQUITY | Oct 12, 2026, 01:32 PM UTC
M
Dexcom schedules Q3 2026 earnings release for Oct. 29
Dexcom plans to release its third-quarter 2026 financial results after market close on October 29, 2026, followed by a 4:30 p.m. Eastern conference call.
EQUITY | Oct 07, 2026, 12:30 PM UTC
L
Why DexCom Could Be the Big Winner Out of Oura's IPO — Barrons.com
By Paul R. La MonicaThere just might be two winners when smart ring maker Oura goes public. Oura, of course, and glucose monitoring company DexCom, which invested $75 million two years ago.We'll know in a matter of days,
EQUITY | Sep 28, 2026, 08:25 PM UTC
H
The Insider Report: The Leaders Have Taken Off
Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the fou
LIVE | Sep 28, 2026, 12:46 PM UTC
M
DexCom price target raised to $102 from $93 by Truist
Truist Securities raised its DexCom price target to $102.00 from $93.00.
EQUITY | Sep 18, 2026, 05:00 PM UTC
L
TD Cowen reiterates Buy on DexCom, $95 price target
TD Cowen reiterated a Buy rating on DexCom and set a $95.00 price target, implying 8.0% upside from the $87.93 Sep 17 close.
EQUITY | Sep 18, 2026, 02:54 PM UTC
L
Portfolio check: The biggest SA Quant upgrades over the past week
Recent upgrades and downgrades from Seeking Alpha's Quant Ratings provide tactical ways investors can track shifting momentum and emerging risk, as well as early indicators for bullish or bearish sentiment. Seeking Alpha
NEWS | Sep 15, 2026, 11:17 AM UTC
L
DexCom CFO Sylvain Takes on Additional Role of Operating Chief
By Adam L. CataldoDexCom Chief Financial Officer Jereme Sylvain will take on the additional role of chief operating officer.In his new role, Sylvain's responsibilities will include overseeing global operations and qualit
NEWS | Sep 14, 2026, 10:51 PM UTC
L
Dexcom promotes Jereme Sylvain to EVP, COO and CFO
Dexcom appointed Jereme Sylvain as EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.Original SEC Filing: DEXCOM INC [ DXCM ] - 8-K - Sep. 14, 2026This is an AI-powered summary. It ma
REGULATION | Sep 14, 2026, 08:46 PM UTC
L
DexCom Names Jereme Sylvain to Role of Chief Operating Officer in Addition to His Duties as CFO >DXCM
DexCom Names Jereme Sylvain to Role of Chief Operating Officer in Addition to His Duties as CFO >DXCM
NEWS | Sep 14, 2026, 08:30 PM UTC
L
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer. In
NEWS | Sep 14, 2026, 08:30 PM UTC
L
Dexcom Promotes Jereme Sylvain To Chief Operating Officer >DXCM
Dexcom Promotes Jereme Sylvain To Chief Operating Officer >DXCM
NEWS | Sep 14, 2026, 08:30 PM UTC
L
Dexcom appoints Glenn Boehnlein to board of directors
EQUITY | Sep 10, 2026, 08:19 PM UTC
L
Dexcom appoints Glenn Boehnlein to its board
EQUITY | Sep 10, 2026, 08:18 PM UTC
L
Dexcom appoints Glenn Boehnlein to board effective September 10, 2026
DexCom, Inc. (NASDAQ:DXCM) announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.
EQUITY | Sep 10, 2026, 08:15 PM UTC
H
CONNECT trial results, coverage expansion seen fueling DXCM growth
CONNECT trial results and expanded coverage are expected to drive DXCM growth, with CMS decisions anticipated by mid-2027. Product innovation, including a 15-Day sensor and AI features, supports margin expansion and glob
EARNINGS | Sep 09, 2026, 01:59 PM UTC
M
DXCM CMS decision and 15-Day sensor rollout eyed to lift 2027 growth
DXCM says CMS review tied to type 2 non-insulin coverage, plus its 15-Day sensor and AI features, could support market expansion by mid-2027 and improve growth and margins.
EQUITY | Sep 09, 2026, 01:08 PM UTC
M
DXCM reports $1.21B revenue for nine months ended June 30
DXCM reported revenue of $1.21B for the nine months ended June 30.
EQUITY | Sep 03, 2026, 08:46 PM UTC
L
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services — Barrons.com
By Doug BuschReviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. The review shows which assumptions held and which ones failed
EQUITY | Sep 03, 2026, 05:51 AM UTC
L
DXCM - Dexcom Announces Upcoming Conference Presentation
DXCM - Dexcom Announces Upcoming Conference Presentation
EQUITY | Sep 01, 2026, 12:39 PM UTC
L
Dexcom management to present update at Wells Fargo Healthcare Conference Sept. 9
DexCom (NASDAQ:DXCM) said management will present an update at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. The live webcast starts at about 8:00 AM EDT.
EQUITY | Sep 01, 2026, 12:30 PM UTC
H
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 50 points on Friday. Shares of AXT Inc (NASDAQ: AXTI ) rose sharply after the company reported better-than-expected second-quarter financial results and is
EARNINGS | Jul 31, 2026, 02:05 PM UTC
H
DXCM Raises Guidance After Q2 Beat
DXCM beats Q2 estimates and raises guidance
EQUITY | Jul 31, 2026, 12:12 PM UTC
H
DXCM Q2 EPS $0.70 vs. est. $0.61; Q2 revs rose 13% Y/y to $1.31B vs. est. $1.29B; raises midpoint of 2026 revenue guidance to $5.18-$5.25B,
DXCM Q2 EPS $0.70 vs. est. $0.61; Q2 revs rose 13% Y/y to $1.31B vs. est. $1.29B; raises midpoint of 2026 revenue guidance to $5.18-$5.25B, up 11-13% and said expects 2026 non-GAAP gross profit margin of about 64%; Q2 sa
EARNINGS | Jul 30, 2026, 08:14 PM UTC
H
DXCM Q2 EARNINGS · Adjusted EPS of $0.70 beating expectations of $0.61 · Revenue of $1.31B beating expectations of $1.29B · A
DXCM Q2 EARNINGS · Adjusted EPS of $0.70 beating expectations of $0.61 · Revenue of $1.31B beating expectations of $1.29B · Adjusted operating income of $328.3M beating expectations of $285.5M · Adjusted net income of $2
EARNINGS | Jul 30, 2026, 08:07 PM UTC
H
DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est
DexCom (NASDAQ: DXCM ) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billion-$5.250 billion vs $5.224 billion estimate.
EARNINGS | Jul 30, 2026, 08:02 PM UTC
H
Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7.
Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7.5%, RIVN +/-7.9%, NXT +/-16.8%, MTZ +/-14.6%, AJG +/-7.2%, GH +/-14.1%, CTVA +/-
EARNINGS | Jul 30, 2026, 05:58 PM UTC
H
Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: UBS upgraded Intuitive Surgical (I
EARNINGS | Jul 28, 2026, 01:35 PM UTC
L
BBNX (Buy, $22 PT), DXCM (Buy, $96 PT), PODD (Neutral, $174 PT), TNDM (Neutral, $18 PT) resuming coverage in the Diabetes sector – initiate
BBNX (Buy, $22 PT), DXCM (Buy, $96 PT), PODD (Neutral, $174 PT), TNDM (Neutral, $18 PT) resuming coverage in the Diabetes sector – initiate MMED @ UBS
EQUITY | Jul 28, 2026, 11:50 AM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC
H
DXCM Earnings preview - continue to see DXCM as possessing one of the most attractive earnings growth algorithms in Medtech @ DBAB
DXCM Earnings preview - continue to see DXCM as possessing one of the most attractive earnings growth algorithms in Medtech @ DBAB
EARNINGS | Jul 23, 2026, 12:36 PM UTC
L
DXCM US FDA - selects DexCom as first tempo pilot participant for glucose health program - To select up to Ten tempo pilot participants per
DXCM US FDA - selects DexCom as first tempo pilot participant for glucose health program - To select up to Ten tempo pilot participants per access model clinical use area
REGULATION | Jul 22, 2026, 06:11 PM UTC
L
DexCom selected by FDA as first participant in TEMPO pilot
The U.S. Food and Drug...
REGULATION | Jul 22, 2026, 06:06 PM UTC
L
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
EQUITY | Jul 21, 2026, 12:24 PM UTC
H
What You Missed On Wall Street On Thursday
The major averages closed broadly lower amid a new wave of corporate earnings reports and renewed weakness in the semiconductor space. Earnings season has started off strong this week, as more than 87% of the 40 S&P 500
RATES | Jul 16, 2026, 08:25 PM UTC
H
Midday Fly By: UnitedHealth, United Airlines, GE Aersopace report Q2 beats
The Dow Jones Industrial Average was higher near noon while the S&P 500 and Nasdaq were lower as investors digest a new wave of corporate earnings reports and renewed weakness in the semiconductor space. Markets continue
MACRO | Jul 16, 2026, 04:10 PM UTC
L
DXCM - DexCom Receives Health Canada Authorization For DexCom G7 15 Day CGM System, Offering 15.5-Day Wear, 8.0% MARD Accuracy, And Fewer Se
DXCM - DexCom Receives Health Canada Authorization For DexCom G7 15 Day CGM System, Offering 15.5-Day Wear, 8.0% MARD Accuracy, And Fewer Sensor Changes For Canadians With Diabetes Link To Press Release
GEOPOLITICS | Jul 13, 2026, 08:53 PM UTC
L
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did DexCom, Inc. Insiders Breach their Fiduciary Duties
EQUITY | Jul 03, 2026, 04:27 PM UTC
M
DXCM Advances Glucose Biosensing
Dexcom further advances its vision of glucose biosensing for all
EQUITY | Jun 23, 2026, 01:00 PM UTC